Jinjun Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinjun Guo has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Guanyi Liao
Department of Gastroenterology and Hepatology, Key Laboratory of Precision Medicine for Digestive System Tumors, Chongqing Municipal Key Laboratory of Institutions of Higher Education, Bishan Hospital of Chongqing Medical University, Chongqing, China
7 shared publicationsHong Peng
Department of Gastroenterology and Hepatology, Key Laboratory of Precision Medicine for Digestive System Tumors, Chongqing Municipal Key Laboratory of Institutions of Higher Education, Bishan Hospital of Chongqing Medical University, Chongqing, 402760, China
7 shared publications- Hong Peng
Department of Gastroenterology and Hepatology, Bishan Hospital of Chongqing, Bishan Hospital of Chongqing Medical University, Chongqing, China
4 shared publications Ke Yin
Chongqing Key Laboratory of Precision Medicine for Digestive System Tumors, Bishan Hospital of Chongqing Medical University
4 shared publicationsQingling Li
College of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China
4 shared publicationsJie Hu
Department of Laboratory Medicine, Bishan Hospital of Chongqing Medical University, Chongqing, 402760, China
3 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Springer Nature in Cancer Cell International
SUCLG2 demethylates GADD45G to activate the p53 pathway and inhibit malignant progression in colorectal cancer
- 8 September 2026
- Published by Springer Nature in Cancer Cell International
Open AccessSUCLG2 demethylates GADD45G to activate the p53 pathway and inhibit malignant progression in colorectal cancer
- Open Access
- 10 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1917544
Targeted plasma lipidomics in non-metastatic colorectal cancer, metastatic colorectal cancer, and healthy controls: an exploratory matched-triplet study
Background: Systemic lipid remodeling accompanies colorectal cancer (CRC), but whether circulating lipid alterations specifically distinguish metastatic from non-metastatic disease remains uncertain. Methods: This single-center prospective cross-sectional study enrolled newly diagnosed patients with non-metastatic CRC (nmCRC), metastatic CRC (mCRC), and healthy controls (HC) between September and December 2024. Two separate 1:1 nearest-neighbor propensity score matches used the same mCRC cohort as the anchor and histories of diabetes and hyperlipidemia as covariates. Matching was performed without replacement using a caliper of 0.2 on the raw propensity-score scale. Participant-level linkage generated 20 matched triplets. Fasting plasma samples underwent quantitative targeted lipidomic profiling. Primary lipid comparisons used matched-pair tests with comparison-specific Benjamini-Hochberg correction, and age- and sex-adjusted sensitivity analyses evaluated residual baseline imbalance. Results: Among 1,459 quantified lipids, 72 nominal differential lipids were identified in mCRC versus nmCRC, 186 in nmCRC versus HC, and 222 in mCRC versus HC using paired raw P<0.05. No lipid remained significant after false discovery rate correction in mCRC versus nmCRC, whereas 12 and 30 lipids remained significant in nmCRC versus HC and mCRC versus HC, respectively. After age and sex adjustment, the corresponding FDR-significant counts were 0, 10, and 9. Eight nominal candidates were shared across all three primary comparisons: BMP(14:0_20:0), BMP(14:0_20:1), Cer(d18:1/26:1), PC(18:2_18:2), PC(18:3_20:1), PC(18:3_20:4), PC(20:0_22:5), and PI(20:0_20:4). Conclusion: Plasma lipidomic differences were most reproducible between patients with CRC and healthy controls, particularly between mCRC and HC. Lipid differences between mCRC and nmCRC remained exploratory and hypothesis-generating. These findings indicate systemic lipid remodeling in CRC but do not establish metastasis-specific plasma biomarkers.
- 10 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1917544
Open AccessTargeted plasma lipidomics in non-metastatic colorectal cancer, metastatic colorectal cancer, and healthy controls: an exploratory matched-triplet study
Background: Systemic lipid remodeling accompanies colorectal cancer (CRC), but whether circulating lipid alterations specifically distinguish metastatic from non-metastatic disease remains uncertain. Methods: This single-center prospective cross-sectional study enrolled newly diagnosed patients with non-metastatic CRC (nmCRC), metastatic CRC (mCRC), and healthy controls (HC) between September and December 2024. Two separate 1:1 nearest-neighbor propensity score matches used the same mCRC cohort as the anchor and histories of diabetes and hyperlipidemia as covariates. Matching was performed without replacement using a caliper of 0.2 on the raw propensity-score scale. Participant-level linkage generated 20 matched triplets. Fasting plasma samples underwent quantitative targeted lipidomic profiling. Primary lipid comparisons used matched-pair tests with comparison-specific Benjamini-Hochberg correction, and age- and sex-adjusted sensitivity analyses evaluated residual baseline imbalance. Results: Among 1,459 quantified lipids, 72 nominal differential lipids were identified in mCRC versus nmCRC, 186 in nmCRC versus HC, and 222 in mCRC versus HC using paired raw P<0.05. No lipid remained significant after false discovery rate correction in mCRC versus nmCRC, whereas 12 and 30 lipids remained significant in nmCRC versus HC and mCRC versus HC, respectively. After age and sex adjustment, the corresponding FDR-significant counts were 0, 10, and 9. Eight nominal candidates were shared across all three primary comparisons: BMP(14:0_20:0), BMP(14:0_20:1), Cer(d18:1/26:1), PC(18:2_18:2), PC(18:3_20:1), PC(18:3_20:4), PC(20:0_22:5), and PI(20:0_20:4). Conclusion: Plasma lipidomic differences were most reproducible between patients with CRC and healthy controls, particularly between mCRC and HC. Lipid differences between mCRC and nmCRC remained exploratory and hypothesis-generating. These findings indicate systemic lipid remodeling in CRC but do not establish metastasis-specific plasma biomarkers.
- Open Access
- 8 July 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
RBMX promotes colorectal liver metastasis by stabilizing MTHFD2 mRNA to regulate redox homeostasis
Liver metastasis is the primary cause of mortality in colorectal cancer (CRC), yet the molecular mechanisms driving colorectal liver metastasis (CRLM) remain poorly understood. This study investigates the role of RNA-binding motif protein X (RBMX) in CRLM progression and its underlying mechanisms. RBMX expression and clinical significance were analyzed in public databases (GEO, TCGA) and in-house cohorts. Metastatic function was assessed using in vitro and in vivo models. Mechanistically, RNA sequencing, RNA immunoprecipitation (RIP), and RNA pull-down assays were employed to identify downstream targets. Metabolic profiling, reactive oxygen species (ROS) quantification, and signaling pathway analyses were used to evaluate redox homeostasis. RBMX was upregulated in CRLM tissues and correlated with poor prognosis. It significantly promoted CRC cells migration, invasion, and liver metastasis. Mechanistically, RBMX directly bound to and stabilized MTHFD2 mRNA, increasing its protein abundance. This upregulation rewired one-carbon metabolism to boost NADPH production, effectively buffering intracellular ROS. Consequently, RBMX suppressed ROS-dependent p38/JNK stress signaling, sustaining metastatic cell survival. Our study reveals that RBMX drives CRLM by stabilizing MTHFD2 mRNA to maintain redox homeostasis. This "RBMX-MTHFD2-Redox" axis links RNA stability to metabolic plasticity, representing a novel mechanistic vulnerability in CRLM and promising candidate for preclinical therapeutic development and biomarker investigation.
- 8 July 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessRBMX promotes colorectal liver metastasis by stabilizing MTHFD2 mRNA to regulate redox homeostasis
Liver metastasis is the primary cause of mortality in colorectal cancer (CRC), yet the molecular mechanisms driving colorectal liver metastasis (CRLM) remain poorly understood. This study investigates the role of RNA-binding motif protein X (RBMX) in CRLM progression and its underlying mechanisms. RBMX expression and clinical significance were analyzed in public databases (GEO, TCGA) and in-house cohorts. Metastatic function was assessed using in vitro and in vivo models. Mechanistically, RNA sequencing, RNA immunoprecipitation (RIP), and RNA pull-down assays were employed to identify downstream targets. Metabolic profiling, reactive oxygen species (ROS) quantification, and signaling pathway analyses were used to evaluate redox homeostasis. RBMX was upregulated in CRLM tissues and correlated with poor prognosis. It significantly promoted CRC cells migration, invasion, and liver metastasis. Mechanistically, RBMX directly bound to and stabilized MTHFD2 mRNA, increasing its protein abundance. This upregulation rewired one-carbon metabolism to boost NADPH production, effectively buffering intracellular ROS. Consequently, RBMX suppressed ROS-dependent p38/JNK stress signaling, sustaining metastatic cell survival. Our study reveals that RBMX drives CRLM by stabilizing MTHFD2 mRNA to maintain redox homeostasis. This "RBMX-MTHFD2-Redox" axis links RNA stability to metabolic plasticity, representing a novel mechanistic vulnerability in CRLM and promising candidate for preclinical therapeutic development and biomarker investigation.
- Open Access
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1830599
Association of preoperative CT-derived visceral adipose tissue index with synchronous metastasis and metastasis-free survival after curative-intent surgery in colorectal cancer
Background: To evaluate whether computed tomography (CT)-derived visceral adipose tissue index (VATI) is associated with synchronous metastasis and metastasis-free survival (MFS) after curative-intent surgery in colorectal cancer (CRC). Methods: This retrospective two-center study included patients with newly diagnosed CRC who underwent abdominal CT within 1 month before diagnosis or initial treatment between January 2019 and December 2022 (n = 468; metastatic CRC [mCRC], n = 77; non-metastatic CRC [nmCRC], n = 391). For the synchronous metastasis analysis, mCRC and nmCRC were propensity score matched 1:1 for age, sex, carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), study center, and tumor location (77 pairs), and multivariable logistic regression was performed. For the MFS analysis, the surgical nmCRC cohort was stratified by sex-specific median VATI into low-VATI (n = 195) and high-VATI (n = 196) groups, and Kaplan-Meier and Cox proportional hazards analyses were performed. Among patients who developed postoperative metastasis (n = 96), an exploratory descriptive comparison was performed between early (≤ 2 years, n = 76) and late (> 2 years, n = 20) metastasis groups. Results: After matching, mCRC showed higher subcutaneous adipose tissue index (SATI), VATI, and visceral-to-subcutaneous fat area ratio (VSR) than nmCRC. VATI was independently associated with synchronous metastasis (OR, 1.110; 95% CI, 1.067–1.155; p < 0.001), whereas SATI and VSR were not. In the surgical nmCRC cohort, the high-VATI group had shorter MFS (log-rank p = 0.001). On multivariable Cox analysis, VATI remained independently associated with shorter MFS (HR, 1.017; 95% CI, 1.003-1.032; p = 0.021), together with CA19-9, CEA, N stage, and lymphovascular invasion (LVI). In the exploratory descriptive comparison, no statistically significant differences in body composition metrics were observed between the early and late metastasis groups. Conclusion: Preoperative CT-derived VATI is a reproducible opportunistic imaging biomarker associated with synchronous metastasis and shorter MFS after curative-intent surgery and may help refine risk stratification and postoperative surveillance in CRC, although prospective validation is required before routine clinical application.
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1830599
Open AccessAssociation of preoperative CT-derived visceral adipose tissue index with synchronous metastasis and metastasis-free survival after curative-intent surgery in colorectal cancer
Background: To evaluate whether computed tomography (CT)-derived visceral adipose tissue index (VATI) is associated with synchronous metastasis and metastasis-free survival (MFS) after curative-intent surgery in colorectal cancer (CRC). Methods: This retrospective two-center study included patients with newly diagnosed CRC who underwent abdominal CT within 1 month before diagnosis or initial treatment between January 2019 and December 2022 (n = 468; metastatic CRC [mCRC], n = 77; non-metastatic CRC [nmCRC], n = 391). For the synchronous metastasis analysis, mCRC and nmCRC were propensity score matched 1:1 for age, sex, carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), study center, and tumor location (77 pairs), and multivariable logistic regression was performed. For the MFS analysis, the surgical nmCRC cohort was stratified by sex-specific median VATI into low-VATI (n = 195) and high-VATI (n = 196) groups, and Kaplan-Meier and Cox proportional hazards analyses were performed. Among patients who developed postoperative metastasis (n = 96), an exploratory descriptive comparison was performed between early (≤ 2 years, n = 76) and late (> 2 years, n = 20) metastasis groups. Results: After matching, mCRC showed higher subcutaneous adipose tissue index (SATI), VATI, and visceral-to-subcutaneous fat area ratio (VSR) than nmCRC. VATI was independently associated with synchronous metastasis (OR, 1.110; 95% CI, 1.067–1.155; p < 0.001), whereas SATI and VSR were not. In the surgical nmCRC cohort, the high-VATI group had shorter MFS (log-rank p = 0.001). On multivariable Cox analysis, VATI remained independently associated with shorter MFS (HR, 1.017; 95% CI, 1.003-1.032; p = 0.021), together with CA19-9, CEA, N stage, and lymphovascular invasion (LVI). In the exploratory descriptive comparison, no statistically significant differences in body composition metrics were observed between the early and late metastasis groups. Conclusion: Preoperative CT-derived VATI is a reproducible opportunistic imaging biomarker associated with synchronous metastasis and shorter MFS after curative-intent surgery and may help refine risk stratification and postoperative surveillance in CRC, although prospective validation is required before routine clinical application.
- 30 May 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6420-6429
Development and external validation of a preoperative CT body composition-based model for predicting postoperative metastasis in colorectal cancer: a multicenter retrospective cohort study
Most postoperative metastases in nonmetastatic colorectal cancer (CRC) occur within 2 years after curative-intent surgery, but tools for quantifying early metastasis risk remain limited. We aimed to develop and externally validate a nomogram integrating preoperative CT body composition with clinicopathologic variables. This multicenter retrospective study included 451 patients with nonmetastatic CRC who underwent curative-intent surgery from January 2019 to December 2022. The training cohort comprised 250 patients from the primary center and the validation cohort 201 patients from 2 external centers. L3-level CT was used to quantify visceral adipose tissue index (VATI). Metastasis-free survival was the primary endpoint, and early metastasis was defined as distant metastasis within 24 months. Independent predictors were identified with Cox regression and used to build a nomogram. Postoperative metastasis occurred in 61 of 250 patients (24.4%) in the training cohort and 50 of 201 patients (24.9%) in the validation cohort. Elevated CA19-9, positive N stage, lymphovascular invasion, and higher VATI were independent predictors. The nomogram yielded a C-index of 0.793 in the training cohort and 0.754 in the validation cohort; the 24-month area under the curve was 0.818 and 0.804, respectively. A nomogram combining CT-derived VATI with N stage, CA19-9, and lymphovascular invasion showed good discrimination and calibration for predicting postoperative metastasis and 24-month early metastasis in CRC.
- 30 May 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6420-6429
Development and external validation of a preoperative CT body composition-based model for predicting postoperative metastasis in colorectal cancer: a multicenter retrospective cohort study
Most postoperative metastases in nonmetastatic colorectal cancer (CRC) occur within 2 years after curative-intent surgery, but tools for quantifying early metastasis risk remain limited. We aimed to develop and externally validate a nomogram integrating preoperative CT body composition with clinicopathologic variables. This multicenter retrospective study included 451 patients with nonmetastatic CRC who underwent curative-intent surgery from January 2019 to December 2022. The training cohort comprised 250 patients from the primary center and the validation cohort 201 patients from 2 external centers. L3-level CT was used to quantify visceral adipose tissue index (VATI). Metastasis-free survival was the primary endpoint, and early metastasis was defined as distant metastasis within 24 months. Independent predictors were identified with Cox regression and used to build a nomogram. Postoperative metastasis occurred in 61 of 250 patients (24.4%) in the training cohort and 50 of 201 patients (24.9%) in the validation cohort. Elevated CA19-9, positive N stage, lymphovascular invasion, and higher VATI were independent predictors. The nomogram yielded a C-index of 0.793 in the training cohort and 0.754 in the validation cohort; the 24-month area under the curve was 0.818 and 0.804, respectively. A nomogram combining CT-derived VATI with N stage, CA19-9, and lymphovascular invasion showed good discrimination and calibration for predicting postoperative metastasis and 24-month early metastasis in CRC.
- Top Cited PapersOpen Access
- 2 March 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Artificial intelligence models: transforming early diagnosis and precise treatment of gastrointestinal cancers
Artificial intelligence (AI) has become an integral force in the clinical landscape of gastrointestinal (GI) oncology. Recent advances in model architectures ranging from traditional machine learning and convolutional neural networks (CNNs) to transformer-based foundational models and graph neural networks (GNNs) have enabled the extraction of complex features from diverse data modalities, including endoscopic images, radiology, pathology whole-slide images, and multi-omics profiles. In this review, AI models are systematically classified into supervised learning, unsupervised clustering, multimodal fusion, and interpretable modeling. The advantages of each model are delineated in unravelling tumor heterogeneity, anatomical characteristics, and treatment-relevant biomarkers. Furthermore, three types of clinical application are emphasized: (1) early screening and lesion localization via segmentation or anomaly detection; (2) molecular subtyping and patient stratification for diagnosis with risk assessment; (3) therapy guidance through response prediction and personalized treatment planning. We also discuss major challenges on the application of AI in integration of heterogeneous clinical data, model generalizability across centers, and the interpretability of predictions. Collectively, this review highlights the transformative potential of AI in better understanding tumor biology and its clinical value in advancing personalized medicine for GI cancer patients.
- 2 March 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Top Cited PapersOpen AccessArtificial intelligence models: transforming early diagnosis and precise treatment of gastrointestinal cancers
Artificial intelligence (AI) has become an integral force in the clinical landscape of gastrointestinal (GI) oncology. Recent advances in model architectures ranging from traditional machine learning and convolutional neural networks (CNNs) to transformer-based foundational models and graph neural networks (GNNs) have enabled the extraction of complex features from diverse data modalities, including endoscopic images, radiology, pathology whole-slide images, and multi-omics profiles. In this review, AI models are systematically classified into supervised learning, unsupervised clustering, multimodal fusion, and interpretable modeling. The advantages of each model are delineated in unravelling tumor heterogeneity, anatomical characteristics, and treatment-relevant biomarkers. Furthermore, three types of clinical application are emphasized: (1) early screening and lesion localization via segmentation or anomaly detection; (2) molecular subtyping and patient stratification for diagnosis with risk assessment; (3) therapy guidance through response prediction and personalized treatment planning. We also discuss major challenges on the application of AI in integration of heterogeneous clinical data, model generalizability across centers, and the interpretability of predictions. Collectively, this review highlights the transformative potential of AI in better understanding tumor biology and its clinical value in advancing personalized medicine for GI cancer patients.
- 9 December 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 337, 149541
From chronic gastritis to gastric cancer: Mendelian randomisation and multi-omics interrogation of leukaemia inhibitory factor receptor (LIFR), hepatocyte growth factor (HGF), serine protease inhibitor E1 (SERPINE1) and interleukin-10 receptor subunit beta (IL10RB)
- 9 December 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 337, 149541
From chronic gastritis to gastric cancer: Mendelian randomisation and multi-omics interrogation of leukaemia inhibitory factor receptor (LIFR), hepatocyte growth factor (HGF), serine protease inhibitor E1 (SERPINE1) and interleukin-10 receptor subunit beta (IL10RB)
- 16 November 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 168 (Pt 1) , 115830
Tumor-derived C4BPA promotes macrophage M2-like polarization through C5a -C5aR1-STAT3 axis and drives gastric cancer progression
- 16 November 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 168 (Pt 1) , 115830
Tumor-derived C4BPA promotes macrophage M2-like polarization through C5a -C5aR1-STAT3 axis and drives gastric cancer progression
- 8 September 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (4) , 1734-1742
CT-based abdominal fat parameters as predictors of recurrence-free survival after radical resection of colorectal cancer: a nomogram approach
Objective This study aimed to create and validate a nomogram to predict early recurrence (ER) in Colorectal cancer (CRC) patients by combining CT-derived abdominal fat parameters with clinical and pathological characteristics. Methods We conducted a retrospective analysis of 206 CRC patients, dividing them into training (n = 146) and validation (n = 60) cohorts. We quantified abdominal fat parameters, including subcutaneous adipose tissue index (SATI) and visceral adipose tissue index (VATI), using semi-automatic software on CT images at the level of the third lumbar vertebra (L3). We calculated the liver fat fraction (LFF) based on the liver CT value (LFF% = -0.58 × [CT-HU] + 38.2). Finally, we performed Cox regression analysis to identify independent predictors of ER. We constructed a nomogram based on these predictors and evaluated its performance using calibration curves, the concordance index (C-index), and area under the curve (AUC). Internal validation was performed using a 1000-bootstrap resampling method. Results LFF, VATI, CEA level, and lymphovascular invasion (LVI) were independent risk factors for ER. The calibration curve showed good concordance, with C-indices of 0.866 (95% CI: 0.808–0.924) and 0.825 (95% CI: 0.736–0.914) in the training and validation cohorts, respectively. Risk stratification effectively distinguished low- and high-risk groups (P < 0.001 for both). Conclusion A nomogram combines CT-derived abdominal fat parameters with clinical data showed good performance in predicting ER in CRC patients, and provides a tool for personalized monitoring and treatment strategies.
- 8 September 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (4) , 1734-1742
CT-based abdominal fat parameters as predictors of recurrence-free survival after radical resection of colorectal cancer: a nomogram approach
Objective This study aimed to create and validate a nomogram to predict early recurrence (ER) in Colorectal cancer (CRC) patients by combining CT-derived abdominal fat parameters with clinical and pathological characteristics. Methods We conducted a retrospective analysis of 206 CRC patients, dividing them into training (n = 146) and validation (n = 60) cohorts. We quantified abdominal fat parameters, including subcutaneous adipose tissue index (SATI) and visceral adipose tissue index (VATI), using semi-automatic software on CT images at the level of the third lumbar vertebra (L3). We calculated the liver fat fraction (LFF) based on the liver CT value (LFF% = -0.58 × [CT-HU] + 38.2). Finally, we performed Cox regression analysis to identify independent predictors of ER. We constructed a nomogram based on these predictors and evaluated its performance using calibration curves, the concordance index (C-index), and area under the curve (AUC). Internal validation was performed using a 1000-bootstrap resampling method. Results LFF, VATI, CEA level, and lymphovascular invasion (LVI) were independent risk factors for ER. The calibration curve showed good concordance, with C-indices of 0.866 (95% CI: 0.808–0.924) and 0.825 (95% CI: 0.736–0.914) in the training and validation cohorts, respectively. Risk stratification effectively distinguished low- and high-risk groups (P < 0.001 for both). Conclusion A nomogram combines CT-derived abdominal fat parameters with clinical data showed good performance in predicting ER in CRC patients, and provides a tool for personalized monitoring and treatment strategies.
- Open Access
- 1 June 2025
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 12, 167-179
Long non-coding RNA ANRIL/p65 negative feedback loop protects intestinal barrier function in inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) demonstrate varying expression levels of long non-coding RNAs (lncRNAs) in their intestinal mucosa, which can potentially impact the function of the intestinal barrier. This impact may occur through the modulation of epithelial cell apoptosis, alteration of intestinal mucosal barrier permeability, and enhancement of inflammatory responses. The objective of this study was to explore the role and underlying mechanisms of the downregulated lncRNA ANRIL in modulating intestinal barrier function in IBD. Notably, ANRIL was found to be significantly downregulated in patients diagnosed with ulcerative colitis (UC), correlating strongly with disease progression. The overexpression of ANRIL in mice treated with dextran sulfate sodium (DSS) resulted in a significant reduction in colonic damage. This was accompanied by the suppression of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β, and an improvement in intestinal barrier function. Transcriptome sequencing following overexpression of ANRIL revealed a significant enrichment of the NF-κB signaling pathway. In both DSS-induced mouse colitis and LPS-induced FHC cell models, the upregulation of ANRIL effectively suppressed the activation of the NF-κB pathway. Furthermore, our findings demonstrated that ANRIL competes with YY1 for binding, thereby inhibiting the interaction between YY1 and p65 subunit of NF-κB. This disruption in interaction results in the suppression of transcriptional activation of NF-κB p65, leading to a reduced expression of inflammatory cytokines and the promotion of intestinal barrier function in IBD.Additionally, we identified a negative feedback loop involving ANRIL and p65, wherein p65 binds to the ANRIL promoter, promoting ANRIL expression. In summary, the ANRIL/p65 negative feedback loop represents a potential therapeutic target for protecting intestinal barrier function in IBD.
- 1 June 2025
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 12, 167-179
Open AccessLong non-coding RNA ANRIL/p65 negative feedback loop protects intestinal barrier function in inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) demonstrate varying expression levels of long non-coding RNAs (lncRNAs) in their intestinal mucosa, which can potentially impact the function of the intestinal barrier. This impact may occur through the modulation of epithelial cell apoptosis, alteration of intestinal mucosal barrier permeability, and enhancement of inflammatory responses. The objective of this study was to explore the role and underlying mechanisms of the downregulated lncRNA ANRIL in modulating intestinal barrier function in IBD. Notably, ANRIL was found to be significantly downregulated in patients diagnosed with ulcerative colitis (UC), correlating strongly with disease progression. The overexpression of ANRIL in mice treated with dextran sulfate sodium (DSS) resulted in a significant reduction in colonic damage. This was accompanied by the suppression of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β, and an improvement in intestinal barrier function. Transcriptome sequencing following overexpression of ANRIL revealed a significant enrichment of the NF-κB signaling pathway. In both DSS-induced mouse colitis and LPS-induced FHC cell models, the upregulation of ANRIL effectively suppressed the activation of the NF-κB pathway. Furthermore, our findings demonstrated that ANRIL competes with YY1 for binding, thereby inhibiting the interaction between YY1 and p65 subunit of NF-κB. This disruption in interaction results in the suppression of transcriptional activation of NF-κB p65, leading to a reduced expression of inflammatory cytokines and the promotion of intestinal barrier function in IBD.Additionally, we identified a negative feedback loop involving ANRIL and p65, wherein p65 binds to the ANRIL promoter, promoting ANRIL expression. In summary, the ANRIL/p65 negative feedback loop represents a potential therapeutic target for protecting intestinal barrier function in IBD.